Ann Intern Med: Helicobacter pylori eradication rate based on rifabutin-based triple therapy (RHB-105)

!---- Background: Helicobacter pylori, which lives in the helicosis of the human body and is one of the most common bacterial pathogensmost of the world's population has been infected with Helicobacter pylori, and in some countries almost 90 percent of people have been infected with the bacteriathe first infection of Hpylori population early atrophic gastritis and stomach cancer incidence is high, Helicobacter pylori infection and stomach cancer mortality rate showed a parallel relationship67% to 80% of stomach ulcers and 95% duodenal ulcers are caused by Helicobacter pyloriwhile there is consensus in support of the eradication of Hpylori infection, resistance to most therapies currently significantly reduces the rate of hinge eradicationDesign: This study is a two-blind Phase III trial conducted at 55 clinical research centers in the United States to evaluate the eradication of Helicobacter pylori in a new treatment based on rifabutinrecruit adults with upper abdominal discomfort and confirmation of infection and untreated adultsintervention: RHB-105 (amoxicillin 3g, omeprazole 120 mg; liverbitin 150 mg), control (amoxicillin 3g, omeprazole 120 mg), course of course 14 daystest: 4 weeks after treatment, C urea exhalation testresult: a total of 445 subjects were recruitedin the intended treatment population, the eradication rate of RHB-105 patients was 83.8% (95% CI 78.4% to 88.0%), significantly higher than in the control group (57.7% (95% CI 51.2% to 64.0%) ;p.lt;001)RHB-105, the rate of helicobacter pylori eradication was not affected by clathromycin or methazole resistanceand no rifobbuttin resistance was detectedthe most common adverse events (incidence of 5%) were diarrhea (RHB-105 10.1% vs control group 7.9%), headache (7.5% vs 7.0%) and nausea (4.8% vs 5.3%)limitation: The subjects did not include people of Asian descent because of the higher incidence of poor metabolism of cytochrome P450 2C19 in the population of Asian descent Conclusion: This study suggests that RHB-105 may be used as a first-line empirical therapy to address the current challenge of increasing antibiotic resistance